InsidersTradesSigma
Follow the Kineta, Inc./de share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Kineta, Inc./de has recorded 50 insider filings. The latest transaction was filed on 2 July 2025 (Disposition). Among the most active insiders: Bartoszek Raymond J.. The full history is free.
50
Insider Decl.
n/a
Thresholds
€121,014
12 ops.
Buy Volume
€16,165
13 ops.
Sell Volume
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 July 2025
Declarations50 total
17,794 sharesCommon StockSEC:0000950170-25-092989:0
860,377 sharesCommon StockSEC:0000950170-25-093082:0
247,933 sharesCommon StockSEC:0000950170-25-093075:0
13,794 sharesCommon StockSEC:0000950170-25-093062:0
165,156 sharesCommon StockSEC:0000950170-25-093051:0
217,333 sharesCommon StockSEC:0000950170-25-093045:0
298,464 sharesCommon StockSEC:0000950170-25-093029:0
101,891 sharesCommon StockSEC:0000950170-25-093015:0
31,000 sharesCommon StockSEC:0000950170-25-093004:0
16,571 sharesCommon StockSEC:0000950170-25-092994:0
12,500 shares@ US$0.61116.4% of flowCommon StockSEC:0000950170-25-090568:0
12,500 shares@ US$0.611100.0% of flowCommon StockSEC:0000950170-25-090145:0
12,500 shares@ US$0.61166.1% of flowCommon StockSEC:0000950170-25-090144:0
12,500 shares@ US$0.61180.6% of flowCommon StockSEC:0000950170-25-090141:0
12,500 shares@ US$0.611100.0% of flowCommon StockSEC:0000950170-25-090140:0
12,500 shares@ US$0.611100.0% of flowCommon StockSEC:0000950170-25-090137:0
225,000 shares@ US$0.3681.2% of flowCommon StockSEC:0000950170-25-090134:0
225,000 shares@ US$0.3678.8% of flowCommon StockSEC:0000950170-25-090132:0
12,500 shares@ US$0.6111.3% of flowCommon StockSEC:0000950170-25-090129:0
225,000 shares@ US$0.3675.0% of flowCommon StockSEC:0000950170-25-090127:0
8,158 shares@ US$0.1412.2% of flowCommon StockSEC:0000950170-25-088521:0
903,995 shares@ US$0.553191.0% of flowCommon StockSEC:0000950170-24-052230:0
1,000 shares@ US$4.3250.8% of flowCommon StockSEC:0001209191-23-057673:0
Canonical exit: 3 Mar 2024 (T+90)
900 shares@ US$3.32788.1% of flowCommon StockSEC:0001209191-23-056995:0
Canonical exit: 26 Feb 2024 (T+90)
3,000 shares@ US$3.270755.5% of flowCommon StockSEC:0001209191-23-056996:0
Canonical exit: 26 Feb 2024 (T+90)
25 of 50 declarations
关于 Kineta, Inc./de
Kineta, Inc./DE 是一家在美国纳斯达克市场上市的生物技术公司，股票代码为 KANT。该公司目前的法人形式是与 Yumanity Therapeutics 进行反向合并后形成的，该合并于 2022 年 12 月完成，之后 Yumanity 更名为 Kineta, Inc.。根据美国证券交易委员会（SEC）的文件，Kineta 被描述为一家临床阶段的生物技术公司，总部位于美国华盛顿州默瑟岛。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001445283/000119312522311158/d407996dex991.htm?utm_source=openai)) Kineta 的业务围绕下一代免疫疗法构建，旨在解决癌症免疫抵抗问题。其主要项目是 KVA12123，一种抗 VISTA 单克隆抗体，旨在靶向肿瘤微环境和免疫疗法抵抗中涉及的检查点通路。该公司还披露了一种处于临床前开发阶段的抗 CD27 激动剂抗体。作为一家开发阶段的生物技术公司，Kineta 依赖于研发执行、临床进展、知识产权保护、监管批准和持续的外部融资，而非产品销售。([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai)) 从竞争角度来看，Kineta 在拥挤的肿瘤学领域中是一个利基的、科学驱动的参与者，该领域由规模更大、资本更雄厚的制药和生物技术集团主导。其潜在的差异化优势来自于对先天免疫和免疫抵抗生物学的关注，管理层强调这是获得差异化免疫肿瘤资产的途径。与此同时，Kineta 反复披露了早期上市生物技术公司的典型风险：有限的运营历史、无商业收入、对资本市场的依赖以及需要通过昂贵的临床里程碑推进资产。([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai)) 最近最重要的进展是 TuHURA Biosciences 于 2025 年 6 月 30 日宣布并完成了对 Kineta 的收购。该交易包括 Kineta 对 KVA12123 的权利，该产品更名为 TBS-2025。因此，KANT 应主要被视为一个已转型为被收购资产的传统上市公司故事，而非一个持续运营的独立上市生物技术公司。对于投资者而言，关键的启示是 Kineta 的价值主张与单一核心免疫肿瘤平台相关联，并最终通过并购而非独立商业化实现。([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/kant-20250630.htm?utm_source=openai))
